NCT03847506View on ClinicalTrials.gov

Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets

PHASE4CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

July 5, 2018

Primary Completion Date

December 2, 2020

Study Completion Date

December 2, 2020

Conditions
Hypertension, Hyperlipidemia
Interventions
DRUG

Ezetimibe/Rosuvastatin

Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg + Candesartan cilexetil 8 mg placebo

DRUG

Candesartan cilexetil/Amlodipine besylate

Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg + Ezetimibe/Rosuvastatin 10 mg/10 mg placebo + Candesartan cilexetil 8 mg placebo

DRUG

Candesartan cilexetil

Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil 8 mg + Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg placebo

Trial Locations (1)

13620

Bundang Seoul National University Hospital, Gyeonggi-do

Sponsors
All Listed Sponsors
lead

HK inno.N Corporation

INDUSTRY